ArticleFrontiers in physiology2026
Integration of neutrophil to high-density lipoprotein ratio for prognostic assessment of nasopharyngeal carcinoma: a large-scale long-term retrospective study.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent research suggests that the emerging neutrophil to high-density lipoprotein ratio (NHR) has a significant correlation with the survival outcomes across a range of tumors. However, its prognostic value in nasopharyngeal carcinoma (NPC) remained to be elucidated. This study aimed to evaluate the relationship between NHR and overall survival (OS) in patients with NPC, as well as to develop a corresponding prognostic model. Methods: We conducted a retrospective analysis of 834 NPC patients who received platinum-based concurrent chemoradiotherapy (CCRT) between January 2010 and December 2014. The optimal NHR cutoff was determined using maximally selected rank statistics. Survival analyses were performed using Kaplan-Meier methods and Cox regression models. A prognostic nomogram incorporating NHR with conventional risk factors was developed and validated. Results: The NHR score successfully segregated NPC patients into two categories with significantly different OS (HR = 0.672, 95% CI: 0.481-0.939, P = 0.019). Multivariate analysis confirmed NHR as an independent prognostic factor, along with age, T stage, and N stage. Considering EBV-DNA is a well-established prognostic factor for NPC in accordance with clinical practice and previous studies, we incorporated it together with the above factors to construct the prognostic nomogram. The established nomogram showed modestly higher predictive accuracy (C-index = 0.696, 95% CI: 0.654-0.738) compared to conventional staging parameters (C-index = 0.648, 95% CI: 0.583-0.713). Conclusion: Pre-treatment NHR serves as an independent prognostic indicator for survival in NPC patients undergoing CCRT. This readily available, cost-effective biomarker, when integrated with traditional prognostic factors, provides a comprehensive tool for risk stratification and treatment planning. External validation through multicenter studies is warranted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.